tiprankstipranks
Amicus sees FY23 Galafold revenue growth between 12%-17% at CER
The Fly

Amicus sees FY23 Galafold revenue growth between 12%-17% at CER

For the full-year 2023, the Company anticipates total Galafold revenue growth between 12 and 17% at CER1 driven by continued underlying demand from both switch and treatment-naive patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan. Non-GAAP operating expense guidance for the full-year 2023 is $340 million to $360 million, driven by prudent expense management offset by continued investment in the global Galafold launch, AT-GAA clinical studies and pre-launch activities, in addition to certain non-recurring costs for manufacturing to support the global launch of AT-GAA4. The Company is on-track to achieve non-GAAP profitability2 in the second half of 2023.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on FOLD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles